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ABSTRACT
Objectives The aim of this preplanned secondary
analysis of a 12-month randomised controlled trial was
to investigate the effects of a multicomponent exercise
programme combined with daily whey protein, calcium
and vitamin D supplementation on cognition in men with
prostate cancer treated with androgen deprivation therapy
(ADT).
Design 12-month, two-arm, randomised controlled trial.
Setting University clinical exercise centre.
Participants 70 ADT-treated men were randomised to
exercise-training plus supplementation (Ex+ Suppl, n=34)
or usual care (control, n=36).
Intervention Men allocated to Ex + Suppl undertook
thrice weekly resistance training with weight-bearing
exercise training plus daily whey protein (25 g), calcium
(1200 mg) and vitamin D (2000 IU) supplementation.
Primary and secondary outcome measures Cognition
was assessed at baseline, 6 and 12 months via a
computerised battery (CogState), Trail-making test, Rey
auditory-verbal learning test and Digit span. Data were
analysed with linear mixed models and an intention-to-
treat and prespecified per-protocol approach (exercise-
training: ≥66%, nutritional supplement: ≥80%).
Results Sixty (86%) men completed the trial (Ex + Suppl,
n=31; control, n=29). Five (7.1%) men were classified
as having mild cognitive impairment at baseline. Median
(IQR) adherence to the exercise and supplement was 56%
(37%–82%) and 91% (66%–97%), respectively. Ex +
Suppl had no effect on cognition at any time.
Conclusions A 12-month multicomponent exercise training
and supplementation intervention had no significant effect
on cognition in men treated with ADT for prostate cancer
compared with usual care. Exercise training adherence
below recommended guidelines does not support cognitive
health in men treated with ADT for prostate cancer.

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ Strengths of this study included the use of objective

⇒

⇒

⇒

⇒

cognitive function tests validated in patients with
cancer and assessing domains recommended by
the International Cancer and Cognition Task Force.
A further strength is the randomised controlled design of the study, whereby androgen deprivation
therapy-
treated men with prostate cancer were
allocated to an exercise training and nutritional supplementation intervention or usual care control.
A limitation of this study is that only five (7.1%) men
were classified as having mild cognitive impairment
at baseline.
This was a secondary analysis of a randomised controlled trial designed to primarily detect change in
bone-based outcomes.
A further limitation is the suboptimal adherence to
the exercise intervention.

Trial registration number Australian and New Zealand
Clinical Trial Registry (ACTRN12614000317695, registered
25/03/2014) and acknowledged under the Therapeutic
Goods Administration Clinical Trial Notification Scheme
(CT-2015-CTN-03372-1 v1).

INTRODUCTION
Prostate cancer (PCa) is the second most
frequently diagnosed cancer in male worldwide, with a projected incidence of 1.6 million
in 2021.1 Androgen deprivation therapy
(ADT) for local and advanced PCa is effective
at reducing androgens, such as testosterone,
to castration levels (<1.7 nmol/L) and thus
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Combining progressive resistance training with an
adequate intake of dietary protein is recommended
to mitigate muscle loss associated with ageing.16 This
is important given that muscle loss is associated with
reduced muscle strength and impaired muscle function (eg, gait speed), all of which have been implicated
with compromised cognitive function.16 Preserving or
improving muscle mass, strength and physical function
may provide health benefits that offset cerebrovascular
and neurological functional declines occurring with
cognitive ageing. Secondary analyses of data from two
parallel 24-week RCTs including 127 frail/prefrail older
adults (≥65 years) observed that combined progressive
resistance training and protein supplementation (15 g
whey protein concentrate 80%) improved information
processing speed, but had inverse associations with verbal
fluency when compared with progressive resistance
training and placebo supplementation.17 However, a
24-week follow-up may have been insufficient to observe
cognitive ageing in the control group.17 Whether a synergistic effect of protein supplementation and exercise
training occurs for cognition in men treated with ADT
is unknown, yet warrants investigation given burgeoning
evidence for exercise and dietary approaches to address
adverse treatment-
related effects. Therefore, the aim
of this study, which represents a secondary analysis of a
12-month RCT, was to investigate the effects of a multicomponent resistance-
based exercise programme with
daily protein, vitamin D and calcium supplementation on
cognitive function compared with usual care in PCa survivors treated with ADT.
METHODS
Study design
As reported previously,18 this study was a 12-
month,
single-blinded, two-arm RCT involving men aged 50–85
years currently undergoing continuous ADT (>3 months)
treatment for PCa. The study was conducted from April
2014 to November 2017. The primary aim of this study
was to examine the effects of the intervention on bone
mineral density,19 which have been reported elsewhere.18
This study represents analysis of secondary outcomes
regarding cognitive function. The study methods and
protocol have been described in detail previously.19
Briefly, all assessments aside from pathology were
conducted at Deakin University, Melbourne. Participants
were randomised (1:1 ratio) after baseline assessment
by an independent researcher using automated random
number sequencing. Allocation was block stratified by age
(<65 or ≥65 years) and body mass index (BMI; <30 and
≥30 kg/m2) to either: (1) multicomponent exercise intervention including progressive resistance training, body-
weight impact and balance exercises, as well as a daily
nutritional supplement containing whey protein, calcium
and vitamin D (Ex + Suppl), or (2) usual care control
receiving 1000 IU vitamin D only. Follow-up assessments
were conducted at 6 and 12 months. Participants were
Mundell NL, et al. BMJ Open 2022;12:e060189. doi:10.1136/bmjopen-2021-060189
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inhibiting tumour progression.2 However, testosterone
reduces the production of a highly neurotoxic protein
(amyloid beta peptide 40), which is linked with the development of dementia and Alzheimer’s disease.3 In older
men with PCa, ADT has been associated with an increased
risk of developing dementia (HR (95% CI): 1.21 (1.11
to 1.33)) and Alzheimer’s disease (1.16 (1.09 to 1.24))
compared with non-ADT PCa controls over duration of
≥12 months.4 Indeed, ADT exposure has been associated
with a deterioration in visuomotor, memory and executive function domains of cognitive function,2 5 which may
in part be explained by ADT-induced cardiovascular and
metabolic comorbidities known to underpin cognitive
decline.4 Notably, these declines appear greater than
in men experiencing normal cognitive ageing associated with age-related reductions in testosterone levels.6
Updated guidelines by the International Society of
Geriatric Oncology recommend that clinicians include
cognitive screening and discuss potential adverse effects
of ADT, particularly in older men (>75 years) with PCa.7
Given that therapeutic benefits of existing treatments
for cognitive impairment or dementia are uncertain,8
there is a need to explore viable options for managing
the potential adverse cognitive changes related to ADT
exposure.2
Meta-
analyses suggest that regular exercise training
provides benefits to executive function and memory in
healthy middle-aged and older adults (>50 years),9 as well
as in general population with cancer.10 In older adults
with cognitive impairment, short duration (≤30 min),
high frequency (≥4 per week) exercise training, was
shown to improve global cognition (Cohen’s d: 0.37) and
executive function (Cohen’s d: 0.27).11 Few studies have
examined an effect of exercise training on cognition in
men with PCa. An randomised controlled trial (RCT) of
54 men (mean age: 66 years) receiving various treatments
for PCa found that a 12-
week aerobic and resistance
training programme comprising two supervised and one
home-based session per week had a small non-statistically
significant effect in self-
reported cognition compared
with usual care (Cohen’s d (95% CI): 0.34 (−0.02 to
0.70)), yet this study did not differentiate an independent
effect of ADT.12 Another RCT including 57 men (mean
age: 70 years) with PCa on ADT reported improvements
to subjective cognitive function (QLQ-C30) following 12
weeks of supervised aerobic and progressive resistance
group-
based exercise-
training (2–3 times per week)
compared with usual care (Cohen’s d (95% CI): 0.88
(0.33 to 1.42)).13 Self-reported improvements to cognitive function were also reported following 6 months of
progressive resistance training in 72 ADT-men compared
with usual care, however these were no longer evident
at 12 months.14 Despite these findings, subjective assessment of cognition does not represent a valid assessment
of cognitive performance.2 15 Thus, there is a need for
further intervention studies investigating the effects of
exercise-training on cognition in ADT-treated men with
validated objective cognitive tests.5
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Patient and public involvement
Participants were invited to participate after discussion with and approval from their treating physicians.
Following analysis at completion of the study, participants were provided with an individualised report in
plain language detailing the results of each assessment
in comparison to population norms and/or prior test
results. Selected outcome measures were previously validated in a population with cancer.19 Community presentations were provided to facilitate both recruitment and
dissemination of the results from the study.
Participants
Men aged 50–85 years with PCa pharmacologically
treated with ADT for 12 weeks or greater were recruited
via referral from The Alfred Hospital (Melbourne,
Australia), Peter MacCallum Cancer Centre (Victoria,
Australia), private urology practices (Victoria, Australia),
PCa support groups (Victoria, Australia) and newspaper
advertisements. Exclusion criteria were: (1) inability to
communicate in English; (2) current smoker; (3) body-
weight exceeding 159 kg; (4) pre-
existing disorder or
pharmacotherapy affecting bone, calcium or vitamin D
metabolism; (5) dietary supplementation with protein;
(6) participation in progressive resistance training
(>1 session/week) or weight-
bearing/impact exercise-
training (>150 min/week) within the last 3 months; and
(7) any absolute contraindications to exercise testing.20
Intervention
Multicomponent exercise program
The 12-month exercise-training protocol was designed
to achieve improvements in the primary musculoskeletal
outcomes. Specific details of the multicomponent exercise programme and progressions have been previously
reported.19 In brief, participants allocated to the intervention were asked to complete three sessions per week.
In weeks 1–26, two gym-based sessions were completed
in small groups (~6 men) supervised by an accredited
exercise physiologist (Deakin University Clinical Exercise
Centre, Melbourne), with participants asked to also undertake one home-based session. In weeks 27–52, participants
were supervised for one gym-based session, completed
one independent gym-
based session at a community
gym and one home-based session. All home-based exercise sessions were structured similarly to the gym-based
sessions, but utilising body-weight and resistance bands
(provided). Participants were familiarised with the
home-based programme under supervision before being
provided with instructions and a home exercise card to
complete. Gym-
based sessions (approximately 60 min
duration) commenced with a 5–10 min aerobic warm-up
(eg, treadmill, rower, stationary cycle), 5–6 progressive
resistance exercises incorporating large compound movements using free weights or weight-
training machines
Mundell NL, et al. BMJ Open 2022;12:e060189. doi:10.1136/bmjopen-2021-060189

(two sets, 8–12 repetitions, moderate to hard intensity
(rating of perceived exertion (RPE): 5–8/10)). The resistance training was progressed over time by increasing
the load to repetition ratio. Weight-bearing impact exercises (three sets, 10–20 repetitions), and two (30–60 s or
a given number of repetitions) challenging functional/
mobility/balance exercises and two core/postural exercises were incorporated. Weight-bearing impact exercises
were progressed by increasing jump height, weight, rate
or adding directional change. Progressions were only
implemented when a given exercise was no longer sufficiently challenging (RPE ≤6/10). All programmes were
individually tailored and modified based on individual
considerations (eg, metastases, comorbidities and relative
contraindications).20
Nutritional supplement
Participants in the intervention group were asked to
consume a daily nutritional supplement in addition to
their usual diet, consisting of 25 g of whey protein concentrate 80% (ie, approximately 20 g of the supplement
was protein) containing approximately 2.4 g of leucine,
1200 mg calcium carbonate (equivalent to 480 mg
elemental calcium) and 1000 IU vitamin D (Omniblend,
Campbellfield, Australia). This was prepared with 150 mL
of water and consumed within 1–2 hours of each exercise sessions or prior to breakfast on non-training days.
Participants in the intervention group were also asked to
take a daily vitamin D tablet containing 1000 IU (Ostelin,
Macquarie Park, Australia), increasing daily intakes to
2000 IU.
Usual care control
Participants allocated to the control group received
ongoing care from their physician/specialist and a daily
vitamin D supplement (1000 IU).
Outcome measures
Cognitive tests
The cognitive outcome measures were compiled based on
established guidelines with a focus on domains shown to
be sensitive to disease and treatment-related changes in
patients with cancer.5 15 Standardised validated neuropsychological tests for objective assessment of cognitive function used in this study included: (1) the trail making test
(TMT), a reliable (inter-rater: r=0.74–0.85)21 measure of
psychomotor speed (TMTA), working memory (TMTB)
and executive function (TMTB-
A); (2) the Rey Auditory Verbal Learning Test (RAVLT), a reliable test (ICC:
0.76)22 for verbal memory and learning; (3) the digit
span forwards (DSF) and backwards (DSB) test, a reliable
(inter-rater: r=0.83)23 24 measure of working memory and
processing ability, respectively; and (4) the National Adult
Reading Test (NART), a reliable (Cronbach alpha: 0.93;
test–retest: r=0.98; inter-
rater: r=0.96–0.98)25 measure
of verbal intelligence and estimate of cognitive reserve
(premorbid cognitive function).
3
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required to provide written informed consent and physician approval to participate.
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Anthropometry and blood pressure
Height was measured to the nearest 0.1 cm without shoes,
using a stadiometer (SECA, Hamburg, Germany). Body
mass was measured to the nearest 0.1 kg using electronic
scales (A&D, Tokyo, Japan). BMI was calculated to the
nearest 0.1 kg/m2. Resting blood pressure was measured
after a 10 min rest (seated) using an automatic sphygmomanometer (TM-2655P, A&D, Tokyo, Japan), with three
measurements taken 1 min apart and the mean of the
second and third measurements used.
Demographic, health and medical information
A demographic, clinical and lifestyle questionnaire was
used to obtain information on age, education and clinical and lifestyle information including past and current
medical conditions (including self-reported cardiometabolic conditions: angina/stroke/heart condition,
diabetes, hypertension or hypercholesterolaemia), use
of prescription and non-prescription medications, PCa
diagnosis date, severity (localised, advanced, presence
and location of metastases), treatment history, current
treatment(s) and ADT use. Information related to PCa
was cross-checked against clinical records provided by the
referring clinician.
4

Physical activity and diet
Habitual physical activity levels were assessed using the
Community Healthy Activities Model Programme for
Seniors physical activity questionnaire.31 A 24-hour food
recall questionnaire was used to obtain information on
usual diet, with all dietary data analysed using Australia-
specific software (FoodWorks, Xyris Software, Highgate
Hills, Australia).
Depression and anxiety
The Depression Anxiety and Stress Scale (DASS) was
also administered.32 DASS is valid and reliable measure
of depression, anxiety, stress and general psychological
distress,32 which are commonly affected by PCa diagnosis.33 For each scale component, mild symptoms are
indicated with a score >4 (depression), >3 (anxiety) and
>7 (stress).
Adherence
Adherence to the supplements was assessed using a daily
calendar completed by the participants and counting any
remaining sachets at 6-month and 12-month follow-up.
Exercise training cards were used to monitor exercise
adherence which were collected at 6-month and 12-month
follow-up.
Adverse events
Adverse events were defined by any unfavourable or
unintended health-related event or issue that developed
or worsened during the study period as a result of the
intervention. Adverse events were recorded at exercise
sessions for the Ex +Suppl group and at follow-up testing
sessions for controls.
Statistical analyses
A priori sample size calculations were based on the
primary bone outcomes and are reported in detail elsewhere.19 An additional a priori sample size calculation
was conducted based on the limited research to date in
relevant population groups34 for the RAVLT cognitive test
(sum of trials 1–5; verbal learning) using the following
observations: (1) mean (SD) scores were reported to
decrease 0.98 (5.04) points following 6 months of ADT,34 35
and (2) mean (SD) scores were shown to increase 4.93
(7.81) points following 6 months of resistance training in
older adults (without PCa) with probable mild cognitive
impairment.35 Given the lack of previous data related to
long-
term age-
related and exercise-
related changes in
cognition in men with PCa treated with ADT, we conservatively used these within group changes to estimate our
between-
group effect size after 12 months follow-
up.
Based on these findings, we estimated (two-sample t-test)
that 42 men with PCa treated with ADT (21 per group)
would provide 80% power (p<0.05, two-tailed) to detect
a net difference of 5.9 points (assuming a SD of 5.5) in
RALVT (sum of trials 1–5; verbal learning) from baseline
to 12-month follow-up.
All analyses were conducted using Stata statistical software
V.16 (College Station, Texas, USA). The primary analyses
Mundell NL, et al. BMJ Open 2022;12:e060189. doi:10.1136/bmjopen-2021-060189
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The CogState Brief Battery was also included, which is a
sensitive battery of five computerised cognitive tests, validated in patients with cancer.26 27 These tests are considered reliable (ICC: 0.72–0.93)28 with minimal learning
effects.29 The battery takes 10–20 min to complete and
provides outcomes for: (1) executive function via the
Groton Maze Learning Task, (2) psychomotor function
via the Detection Task, (3) attention via the Identification
Task, (4) visual memory via the One Card Learning Task
and (5) working memory accuracy and visuomotor speed
via the One Back Task.26 27 Prior to commencing each
test, participants were given written and verbal instructions and allowed a practice of each test. Outcomes were
attained for reaction time for accurate responses (in
milliseconds; Identification Task, Detection Task, One
Back Task), percentage of correct responses (One Card
Learning Task) and number of errors on five sequential
trials (Groton Maze Learning Task).26 27 Reaction time
outcomes were analysed after log10 transformation and
percentage of correct response outcomes were analysed
after square root/arcsine transformation. Raw scores
for each test were transformed into a Z-score (using the
mean (SD) of the total sample). Time-based tasks were
multiplied by −1 when converted to z-
scores. Three
composite scores were calculated by averaging z-scores:
(1) global cognition (Detection, Identification, One
Card Learning and One Back task); (2) psychomotor-
attention composite (Detection and Identification) and
(3) working-memory and learning composite (One Card
Learning and One Back Task).26 Higher z-scores indicated better performance for all measure. Mild cognitive
impairment was defined as scoring ≤−1 z-score on three of
the five individual tasks.30

Open access

RESULTS
Participant characteristics
In total, 214 men expressed interest in participating in
the study from which 70 were randomised into Ex + Suppl
(n=34) or CON (n=36) (figure 1). On average, men were
aged 71 years, with 53% and 30% classified as overweight
and obese, respectively (table 1). Collectively, 93% of
men reported the presence of at least one cardiometabolic comorbidity. Mean serum 25-
hydroxyvitamin D
levels were 69.8 nmol/L, with 12 (17%) men classified
as having insufficient levels (<50 nmol/L). Median time
since diagnosis of PCa was 3.3 years and median treatment duration with ADT was 12 months. Overall, 64% of
men were classified as having advanced PCa and 29% as
having bone metastases. Regarding treatment, 49% had
prior prostatectomy, 69% radiotherapy and 16% chemotherapy. Five (7.1%) men had mild cognitive impairment.
Adherence
Ten (14%) of the 70 participants who completed
baseline testing did not complete 12-m onth follow-u p
testing (Ex + Suppl: n=6, CON: n=4). Of the 34 participants randomised to Ex + Suppl, 1 did not commence
the exercise programme due to a perceived lack of
time, while 5 discontinued the exercise programme
Mundell NL, et al. BMJ Open 2022;12:e060189. doi:10.1136/bmjopen-2021-060189

Figure 1 Consolidated Standards of Reporting Trials
diagram of participant flow through the study.

(4 within 3 months and 1 after 9 months) due to
reasons unrelated to the study (health (n=3); lack
of time (n=1); personal reasons (n=1)). Of those
who discontinued with the exercise training, four
men continued with the supplement alone, and five
attended follow-u p testing. Mean (SD) and median
(IQR) exercise adherence was 56% (30%) and 56%
(37%–82%), respectively. Mean (SD) adherence was
higher for the supervised versus unsupervised sessions
(65% (25%) vs 49% (38%)). Mean (SD) adherence to
the nutritional supplement was 77% (30%).
Safety and tolerability
No serious adverse events occurred over the 12-month
intervention period. There were 21 musculoskeletal complaints recorded among 14 (41%) patients.
Of these n=19 were minor (no treatment required)
and resulted in participants either missing or modifying between one and four exercise-t raining sessions
per incident. Two participants required temporary
modification of their programmes (<6 weeks) due to
exacerbation of pre-
e xisting knee problems. Three
participants ceased the nutritional supplement
during the first 6 months due to reported digestive
discomfort.
Prostate cancer treatment
Details regarding treatment types have been previously reported.19 In summary, median ADT duration
was 5 months greater in the control compared with Ex
+ Suppl group (table 1). At 6-month follow-u p, eight
patients (Ex + Suppl: n=1, CON: n=7) had ceased ADT.
Another eight patients (Ex + Suppl: n=4, control:
n=4) stopped ADT between 6-month and 12-month
follow-
u p. The proportion of men stopping ADT
5
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were conducted with an intention-to-treat approach. A
per-protocol analysis was also employed including participants with ≥66% exercise-training and ≥80% nutritional
supplement adherence. Normality of distribution was
assessed using Q–Q plots of residuals from unadjusted
models (online supplemental figure S1). Linear mixed
models with random effects (participants) were used to
evaluate within-
group and between-
group changes by
time and group-by-time interactions (fixed effects) via
the following models: (1) unadjusted; (2) adjusted for
age, BMI, depressive symptoms (DASS), ADT duration,
habitual physical activity, level of education and presence
of cardiometabolic comorbidities (yes/no; hypertension
(systolic ≥130 or diastolic ≥80), dyslipidaemia (cholesterol ≥5.5 mmol/L, low-density lipoprotein-cholesterol
≥3.5 mmol/L,
high-density
lipoprotein-cholesterol
<1.0 mmol/L, triglycerides ≥2.0 mmol/L or taking lipid-
modifying medication)), self-reported diagnosis of type
2 diabetes, cardiovascular disease or if taking cardiometabolic medication); and (3) model 2 plus changes in body
mass. Sensitivity analyses were employed for treatment-
based, disease-based and dietary-based factors. No data
imputations were made as linear mixed models utilised
the maximum likelihood estimation. Changes in proportions of dichotomised cardiometabolic comorbidities
(hypertension, dyslipidaemia, type 2 diabetes, cardiovascular disease, cardiometabolic medication) variables by
time were examined via McNemar test. Differences in
proportions of dichotomised cardiometabolic comorbidities by group were examined via χ2 test. An alpha-level of
0.05 was adopted for all statistical tests.
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Ex + Suppl (n=34)

Control (n=36)

Total (n=70)

71 (6)
175.3 (6.6)

71 (7)
175.0 (6.4)

71 (6)
175.1 (6.4)

87.6 (16.9)

89.4 (17.6)

88.5 (17.1)

Body mass index (kg/m )

28.4 (4.3)

29.2 (5.7)

28.8 (5.1)

 Overweight, n (%)

19 (55.9)

18 (50.0)

37 (52.9)

 Obese, n (%)

10 (29.4)

11 (30.6)

21 (30.0)

Age (years)
Height (cm)
Weight (kg)
2

Cardiometabolic comorbidity*

1.2 (1.0)

1.3 (1.1)

1.2 (1.0)

Prescription medication, n (%)

27 (79.4)

28 (77.8)

55 (78.6)

 If yes, total number of medications

2.7 (1.7)

4.1 (2.5)

3.5 (2.5)

4 (11.8)

1 (2.8)

5 (7.1)

 Completed high school, n (%)

5 (14.7)

6 (16.7)

11 (15.7)

 Tech/trade certificate, n (%)

5 (14.7)

7 (19.4)

12 (17.1)

 Tertiary, n (%)

20 (58.8)

22 (61.1)

42 (60.0)

Physical activity (kJ/day)

3043 (1770)

2248 (1571)

2634 (1706)

 Energy (kJ/day)

8920 (2941)

8412 (2178)

8666 (2579)

 Protein (g/kg/day)

1.12 (0.42)

1.01 (0.28)

1.07 (0.36)

 Carbohydrate (g/day)

219 (99)

210 (76)

214 (87)

 Fat (g/day)

75 (31)

79 (37)

77 (34)

 Calcium (mg/day)

821 (369)

860 (384)

841 (375)

PCa diagnosis (months), median (IQR)

34 (13–78)

53 (17–137)

40 (14–103)

 
Localised/removed

10 (29.4)

10 (27.8)

20 (28.6)

 Advanced

22 (64.7)

23 (63.9)

45 (64.3)

 Unknown

2 (5.9)

3 (8.3)

5 (7.1)

Prostate-specific antigen (µg/L), median (IQR)

0.38 (0.02–1.04)

0.17 (0.02–1.20)

0.28 (0.02–1.04)

ADT duration (months), median (IQR)

8 (4–22)

13 (8–24)

12 (5–23)

Depression Anxiety Stress Scale, points

11.2 (8.9)

8.6 (8.4)

9.9 (8.7)

 Leg press three repetition maximum (kg)

148.6 (29.9)

136.4 (54.0)

142.3 (44.1)

 Chest press three repetition maximum (kg)

34.5 (7.0)

38.9 (10.6)

37.8 (9.2)

 Seated row three repetition maximum (kg)

45.6 (8.8)

48.3 (10.3)

47.0 (9.6)

 30 s sit-to-stand (repetitions)

13.5 (5.5)

12.6 (3.8)

13.0 (4.7)

 Timed up-and-go with cognitive task (seconds)

10.95 (3.04)

11.83 (4.48)

11.40 (3.85)

 Gait speed (seconds)

1.41 (0.16)

1.43 (0.22)

1.42 (0.19)

 400-m walk (seconds)

271.6 (37.1)

290.9 (37.7)

281.53 (38.39)

9.56 (1.69)
55.5 (0.8)

9.62 (2.25)
54.3 (2.6)

9.59 (1.98)
54.9 (2.0)

Education
 Primary or some high school, n (%)

Diet

Stage of PCa, n (%)

Muscle strength

Physical function

Balance/mobility
 Four square step test (seconds)
 Berg balance (points)

Data are mean (SD) unless stated otherwise.
*Angina/stroke/heart condition, diabetes, hypertension or hypercholesterolaemia.
ADT, androgen deprivation therapy; Ex + Suppl, multi-component exercise program combined with protein, calcium and vitamin D
supplementation; PCa, prostate cancer.
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Table 1 Baseline characteristics of participants

Open access
to 6 (both: p>0.157) or 6–12 months (both: p>0.083).
Changes in proportions of men taking cardiometabolic medication did not differ between groups from 0
to 6 months (p=0.435), 0–12 months (p=0.653) or 6–12
months (p=0.596).

Cognitive function
For all measures of cognitive function, whether analysed unadjusted or adjusted for relevant confounders,
there were no significant between-group differences for
the changes after 6 or 12 months (table 2). Both groups
demonstrated improvements in immediate recall (mean
change, Ex + Suppl: 11%, control: 21%), verbal learning
(Ex + Suppl: 13%, control: 12%), visuomotor speed (Ex
+ Suppl: 19%, control: 16%) and task switching (Ex +
Suppl: 16%, control: 21%) after 12 months, with the Ex +
Suppl group also exhibiting improvements in verbal recall
(7.3%), verbal working memory (9.4%) and the CogState
working memory learning score (0.24 z-
scores) after
12 months (table 2). Per-protocol analyses that included
only Ex + Suppl men (n=11) adherent to the intervention (exercise-training ≥66% and nutritional supplement
≥80%) and controls did not alter any of the results related
to the between-group effects. Sensitivity analyses revealed
similar results when models were adjusted for baseline
energy, protein, carbohydrate and fat dietary intake
(online supplemental table S1). Results were also similar
following adjustment for treatment-
based and disease-
based factors: (1) ADT duration at baseline, (2) stopping
ADT during the study, (3) bone metastases at baseline,
(4) starting radiotherapy during the study or (5) starting
chemotherapy during the study (online supplemental
table S2).

DISCUSSION
To our knowledge, this is the first study to investigate
the efficacy of a resistance-based multicomponent exercise intervention combined with a multinutrient supplement on objectively measured cognitive function in
ADT-treated men with PCa. The main findings from this
secondary analysis were that a multicomponent exercise
training and nutritional supplementation intervention
did not improve cognitive function in men treated with
ADT for PCa compared with usual care. Per-protocol analyses (exercise adherence: ≥66%, supplement adherence:
≥80%) yielded similar results, although were limited by
the number of participants meeting adherence criteria
(n=11).
The finding that there was no effect of our exercise
plus nutrition intervention on cognitive function in ADT-
treated men is similar to results from two previous RCTs
which reported no benefits of 12 months of aerobic and
resistance exercise training on a subscale for self-reported
cognition (within the Treatment of Cancer Quality of
Life Questionnaire C30) compared with an educational
material control (ie, patients received printed material regarding physical activity guidelines only) or usual
care.36 The authors noted that individuals with comorbidities were more likely to demonstrate cognitive benefits
from the intervention.36 Our findings also aligned with
those of a RCT that demonstrated a 12-month aerobic
and resistance exercise programme did not improve on
a subscale for self-reported cognition (derived from the
European Organization for Research and Treatment of
Cancer questionnaire for patients with PCa) compared
with usual care in 72 men treated with ADT.14 However
in contrast to our study, prior studies have used self-
reported cognitive assessments derived from subscales
of quality of life questionnaires (rather than objective tests).12 14 36 While our study used robust cognitive
assessments, including domains previously shown to be
affected during ADT, we still did not detect any effect of
multidomain exercise and nutrition intervention of any
measure of cognitive function.15 Of note, only 7.1% of
men in this study were classified as having mild cognitive
impairment at baseline. Collectively, our observations
and those of previous studies suggest that multicomponent exercise training alone or with nutritional support
may not be a viable therapeutic intervention to improve
cognitive function in men treated with ADT for PCa who
are largely cognitively intact.
Several reasons may explain the lack of efficacy of
our multicomponent exercise training and nutritional
supplementation intervention on cognitive function,
despite evidence-based recommendations that exercise

Diet and physical activity
As reported in detail elsewhere,18 there were no significant within-group changes or between-group differences
for daily energy, carbohydrate, protein or fat intake
(excluding the supplements; online supplemental table
S3). Mean (95% CI) habitual physical activity increased
within the control group at 12-month follow-up (453 (70,
835) kJ/day, p=0.040), yet there were no other within-
group changes or between-group differences observed at
any other time-point (online supplemental table S3).
Cardiometabolic comorbidities
The proportions of men with hypertension, dyslipidaemia,
type 2 diabetes and cardiovascular disease did not differ
from 0 to 6, 0–12 or 6–12 months among the total sample,
Ex + Suppl or CON (online supplemental table S4).
Among the total sample, the proportion of men taking
cardiometabolic medication increased 16% from 0 to 12
months (p=0.003) and 7% from 6 to 12 months (p=0.025)
yet did not change from 0 to 6 months (p=0.059). The
proportion of men taking cardiometabolic medication
increased for both Ex + Suppl (14%; p=0.025) and CON
(17%; p=0.046) from 0 to 12 months, yet not from 0
Mundell NL, et al. BMJ Open 2022;12:e060189. doi:10.1136/bmjopen-2021-060189
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did not statistically differ between groups (p=0.114).
Other treatments that commenced during the study
were radiotherapy (Ex + Suppl: n=4), chemotherapy
(Ex + Suppl: n=5, control: n=1) and additional anti-
androgens (ie, combined androgen blockade; Ex
+Suppl: n=4, control: n=3).
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n

26

 ∆ 12 months

0.6 (0.1 to 1.2)

0.9 (0.3 to 1.4)

25
24

0.001
0.024

6.2 (3.1 to 9.3)

27

26

 ∆ 6 months

 ∆ 12 months

31
25
24

–
<0.001
0.001

26

 ∆ 12 months

6.9±3.7

0.8 (0.0 to 1.7)

1.2 (0.4 to 2.1)
24

0.055

0.8 (0.1 to 1.4)

0.2 (−0.5 to 0.9)

10.9±2.6

27

26

 ∆ 6 months

 ∆ 12 months

0.6 (0.0 to 1.2)

−0.1 (−0.7 to 0.4)

6.4±2.0
24

0.041

26

 ∆ 12 months

35.8±14.0

−6.7 (−10.8 to to 2.6)

−2.0 (−6.1 to 2.1)
24

0.002

−9.1 (−18.9 to 0.7)

27

26

 ∆ 6 months

 ∆ 12 months
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25
24

0.070
0.014

–

2.2 (−0.5 to 4.9)

−18.3 (v34.4 to to 2.1)

−16.8 (v32.7 to to 0.9)

85.2±63.3

−5.7 (−9.0 to to 2.4)

−6.2 (−9.5 to to 3.0)

35.2±12.3

−0.1 (−0.8 to 0.6)

−0.3 (−0.9 to 0.4)

6.4±2.1

0.5 (−0.2 to 1.3)

0.2 (−0.5 to 1.0)

10.5±2.5

0.2 (−0.6 to 1.0)

0.5 (−0.2 to 1.3)

8.1±3.0

4.9 (2.1 to 7.6)

−1.1 (−18.9 to 16.6)

–

–

−4.4 (−22.1 to 13.4)

0.039
0.027

–

−1.1 (−6.1 to 4.0)
–

0.001

–
4.4 (−3.4 to 12.2)

–

0.5 (−0.7 to 1.7)

0.0 (−1.1 to 1.1)

–

0.6 (−0.7 to 2.0)

0.4 (−0.9 to 1.7)

–

−0.8 (−2.9 to 1.2)

−0.9 (−2.8 to 1.1)

–

−2.3 (−8.4 to 3.9)

1.0 (−4.8 to 6.8)

–

<0.001

0.786

0.422

–

0.172

0.515

–

0.629

0.188

–

<0.001

0.104

–

−1.0 (−2.1 to 0.0)

0.001

1.2 (0.5 to 2.0)
41.1±10.9

0.4 (−0.4 to 1.3)

–

Net difference (95% CI)

0.976

–

P value

0.0 (−0.7 to 0.7)

5.7±1.9

Mean±SD or (95% CI)

–

0.544

0.414

–

0.716

0.111

–

0.120

0.778

–

0.648

0.902

–

0.273

0.224

–

0.927

0.062

–

0.338

0.077

–

Continued

P value interaction
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Executive function, seconds to complete trial making test B minus trail making test A
27
40.1±31.8
–
31
50.0±54.9
 Baseline

−12.4 (−22.4 to to 2.5)

75.8±40.0

27

 Baseline

31

25

–
0.340

Task switching, seconds to complete trail making test B

27

27

 Baseline

 ∆ 6 months

31

25

0.619

–

Visuomotor speed, seconds to complete trail making test A

27

 Baseline

30

25
24

0.586
0.028

–

Verbal working memory, sequences recalled on digit span backwards

27

26

 ∆ 6 months

27

 ∆ 12 months

 Baseline

31

31
25

–
0.005

Verbal recall, sequences recalled on digit span forwards

27

27

 Baseline

 ∆ 6 months

Delayed recall, words recalled on trial 7 of Rey Auditory Verbal Learning Test

5.1 (2.0 to 8.2)

39.0±9.1

27

 Baseline

Verbal learning, words recalled on trial 1–5 of Rey Auditory Verbal Learning Test

27

 ∆ 6 months

Immediate recall, words recalled on trial 1 of Rey Auditory Verbal Learning Test
27
5.3±1.4
–
31
 Baseline

Control
P value

n

Mean±SD or (95% CI)

Ex + Suppl

Table 2 Mean cognition by domain at baseline, absolute within-group change from baseline and absolute net between-group differences for the change from baseline
to 6-month and 12-month follow-up

Open access

−5.9 (−17.1 to 5.3)

0.305

0.211
24

25
−12.7 (−28.1 to 2.8)

−10.7 (−26.0 to 4.5)

Mean±SD or (95% CI)

30

30

 ∆ 6 months

 ∆ 12 months

−0.21 (−0.48 to 0.06)

−0.31 (−0.59 to to 0.04)

0.29±0.64
24

27

0.025
0.131

34

–
0.080

−0.27 (−0.40 to 0.29)
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30

 ∆ 12 months

0.04±0.71

0.24 (0.02 to 0.47)

0.02 (−0.20 to 0.24)

9

30
30

 ∆ 6 months
 ∆ 12 months

−0.10 (−0.26 to 0.07)
0.08 (−0.09 to 0.24)

0.11±0.56
0.240
0.368

–
27
24

34

24

0.030

34
27

–
0.859

−0.14±0.87

0.01 (−0.15 to 0.18)
0.01 (−0.17 to 0.18)

−0.10±0.81

0.13 (−0.09 to 0.36)

0.01 (−0.21 to 0.22)

0.865
0.938

–

0.244

0.942

0.07 (−0.25 to 0.39)
0.29 (−0.03 to 0.61)

–

0.33 (−0.02 to 0.68)

0.15 (−0.22 to 0.53)

–

0.37 (−0.10 to 0.83)

0.08 (−0.38 to 0.54)

–

−3.3 (−18.0 to 11.4)

−5.5 (−20.6 to 9.5)

Net difference (95% CI)

0.348
0.575

–

0.487

0.944

–

0.765

0.267

–

0.478

0.698

P value interaction
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Baseline values are absolute mean (SD), change values are absolute mean (95% CI) and p value interaction is from the unadjusted model. Ex + Suppl: multicomponent exercise program
combined with protein, calcium and vitamin D supplementation.
Bold value signifies P≤0.05.

31

 Baseline

Global cognition, z-score from CogState composite

31

30

 Baseline

 ∆ 6 months

–

0.566

–

0.107

0.167

P value

−0.09 (−0.38 to 0.21)

−0.04±0.86

Working memory learning, z-score from CogState composite of one back and one card learning tasks

31

 Baseline

Psychomotor attention, z-score from CogState composite of detection and identification tasks

26

 ∆ 12 months

−7.1 (−18.1 to 4.0)

n

27

Control
P value

n

Mean±SD or (95% CI)

Ex + Suppl

Continued

 ∆ 6 months

Table 2
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in part by the sample of men recruited. For example,
cardiometabolic comorbidities in our study were highly
prevalent (93%), which is important as they are associated with accelerated cognitive ageing (eg, cognitive
decline and dementia) due to an overlap in pathogenic
processes.43 Therefore, the cardiometabolic health of
patients in our study may have blunted any potential
improvements in cognitive function associated with our
intervention. Post-hoc exploratory analysis of cardiometabolic outcomes showed no within group improvement
or between-
group differences in hypertension, dyslipidaemia, type 2 diabetes or cardiovascular disease (online
supplemental table S4). Furthermore, the proportion of
men treated with cardiometabolic medication increased
similarly by 14% (p=0.025) for Ex + Suppl and 17%
(p=0.046) for controls over 12-month follow-up. Drug-
related adverse changes to cardiovascular and metabolic
physiology may partially explain the variations within
cognitive status previously reported in ADT-treated men.43
Adaptations to the intervention may have been diminished by the effects of low testosterone levels in our
men which are reported to influence brain plasticity.44
Although we adjusted for baseline duration of ADT, PCa
treatment over the span of 12 months differed between
groups, with 31% (n=11) of controls discontinuing ADT
compared with 15% (n=5) in the intervention group.
Evidence has shown that cognitive decline following
9 months of ADT resolves 3 months following cessation.45 This may in part explain some of the within-group
improvements observed in the control group, as well as
the increase in habitual physical activity when compared
with the intervention group. Our speculation regarding
physical activity is further supported by evidence that
fatigue also resolves 3 months following ADT cessation.45
Additionally, a greater number of intervention group
patients commenced radiotherapy (intervention: n=4
(12%), control: n=0 (0%)) and chemotherapy (intervention: n=5 (15%), control: n=1 (3%)). Both radiotherapy
and chemotherapy are independent risk factors for
cognitive decline in patients with cancer46 ; hence, the
adverse effects associated with these therapies may have
impacted cognitive function within our study. Despite
the randomised design of our study, and adjustment
for baseline treatment history, PCa treatment associated
with cognitive decline appeared to differ between groups
across the duration of the intervention. Although results
were not altered when treatment changes were considered in analyses, the study was not powered to detect
effects of a change in treatment status to cognition and
this should be considered when interpreting our results.
This preplanned secondary analysis was registered with
the larger RCT.19 Strengths of this study included the
use of cognitive function tests validated in patients with
cancer and recommended by the International Cancer
and Cognition Task Force.15 The limitations of the current
study should also be considered when interpreting
results. First, exercise training adherence was suboptimal.
While this may have impacted cognitive function, it does
Mundell NL, et al. BMJ Open 2022;12:e060189. doi:10.1136/bmjopen-2021-060189
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training, and in particular progressive resistance training,
can mitigate cognitive impairment in general population with cancer groups.10 In older adults, exercise
training variables such as adherence, intensity, duration
and mode are important determinants with regard to
exercise-
related changes to cognition.9 Meta-analyses
have shown moderate to large effects to cognition can
occur following aerobic, resistance or combined exercise
in adults aged ≥50 years,9 11 with a duration of 45–60 min
and at a moderate-to-vigorous intensity and with higher
frequencies (eg, most days of the week).9 11 In older adults
with mild cognitive impairment, muscle strength gains
following resistance training were also shown to mediate
improvements in cognition.37 Although we observed
some improvements in muscle strength and function
following the intervention, the magnitude of the changes
were modest (14.5% for muscle strength and 9.3%–10.7%
for function).18 This is likely related to poor adherence
to exercise sessions (mean 56%) within our study. The
reason for the lower adherence to the exercise sessions
in our study may in part stem from our inclusion of unsupervised sessions, completed alone rather than in groups
(mean adherence to the unsupervised sessions was 49%
compared with 65% for supervised sessions). Prior data
from a 12-month intervention in men with PCa, observed
unsupervised adherence (43%) was approximately half
that of supervised sessions (84%).38 We cannot dismiss
that adherence (insufficient frequency, intensity or
volume of exercise) was the primary factor underpinning
our null results.
A lack of improvement in muscle mass and strength
may be instrumental to the absence of improvement in
cognitive function in our study given the neuroprotective
benefits of preserving muscle mass, strength and physical
function.39 Low muscle mass is associated with greater
risk for cognitive decline, particularly when combined
with low strength.40 Contrary to our hypotheses and
reported in detail elsewhere,18 the multicomponent
exercise training and nutritional supplementation intervention in our study had limited effects to strength and
function and did not elicit any significant between-group
improvements in lean mass or muscle cross-sectional area
compared with usual care.18 Reasons may include that
the intervention group patients within our study tended
to have sufficient dietary protein intake (~1.1 g/kg/
day; online supplemental table S3), which is close to the
recommended intake of at least 1.20 g/kg/day for older
adults when undertaking resistance training.41 Similarly,
the 88% (n=71) of men had sufficient baseline serum
25(OH)D (mean: 69.8 nmol/L). Although lower vitamin
D levels (<50 nmol/L) have been associated with lower
scores for global cognition, and higher risk of Alzheimer’s disease,42 both groups of men received a vitamin
D supplement, and as previously reported there were no
significant between-group differences in serum 25(OH)D
status from the intervention.18
The lack of efficacy of our intervention on measures
of cognition in our current study may also be explained
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